Therapeutic approaches to enhance PINK1/Parkin mediated mitophagy for the treatment of Parkinson's disease

Silke Miller (Lead / Corresponding author), Miratul M. K. Muqit

Research output: Contribution to journalReview article

4 Citations (Scopus)
38 Downloads (Pure)

Abstract

The discovery of rare familial monogenic forms of early-onset Parkinson's disease has led to the identification of a mitochondrial quality control process as a key player in this disease. Loss-of-function mutations in the genes encoding PINK1 or Parkin result in insufficient removal of dysfunctional mitochondria through autophagy, a process termed mitophagy. Understanding the mechanism of this process and the function of its two key players, PINK1 and Parkin, has led to the discovery of new therapeutic approaches. Small molecule activators of mitophagy, either activating PINK1 or Parkin directly or inhibiting Parkin's counterplayer, the ubiquitin-specific protease USP30, are in preclinical development. To enable clinical success of future small molecule mitophagy enhancers, biomarkers for mitochondrial integrity and mitophagy are being developed. Only a few years after the discovery of mitophagy deficits in Parkinson's disease, research of the underlying mechanisms, drug discovery of modulators for this mechanism and identification of biomarkers provide new avenues towards the development of disease-modifying therapies.

Original languageEnglish
Pages (from-to)7-13
Number of pages7
JournalNeuroscience Letters
Volume705
Early online date14 Apr 2019
DOIs
Publication statusPublished - 13 Jul 2019

Fingerprint

Mitochondrial Degradation
Parkinson Disease
Biomarkers
Ubiquitin-Specific Proteases
Therapeutics
Autophagy
Drug Discovery
Quality Control
Mitochondria
Mutation
Research
Genes

Keywords

  • Parkinson's disease
  • Mitophagy
  • PINK1
  • Parkin
  • USP30
  • Small molecule

Cite this

@article{03d1ad617ab547ed819894c8bd81eedf,
title = "Therapeutic approaches to enhance PINK1/Parkin mediated mitophagy for the treatment of Parkinson's disease",
abstract = "The discovery of rare familial monogenic forms of early-onset Parkinson's disease has led to the identification of a mitochondrial quality control process as a key player in this disease. Loss-of-function mutations in the genes encoding PINK1 or Parkin result in insufficient removal of dysfunctional mitochondria through autophagy, a process termed mitophagy. Understanding the mechanism of this process and the function of its two key players, PINK1 and Parkin, has led to the discovery of new therapeutic approaches. Small molecule activators of mitophagy, either activating PINK1 or Parkin directly or inhibiting Parkin's counterplayer, the ubiquitin-specific protease USP30, are in preclinical development. To enable clinical success of future small molecule mitophagy enhancers, biomarkers for mitochondrial integrity and mitophagy are being developed. Only a few years after the discovery of mitophagy deficits in Parkinson's disease, research of the underlying mechanisms, drug discovery of modulators for this mechanism and identification of biomarkers provide new avenues towards the development of disease-modifying therapies.",
keywords = "Parkinson's disease, Mitophagy, PINK1, Parkin, USP30, Small molecule",
author = "Silke Miller and Muqit, {Miratul M. K.}",
note = "Funding: Wellcome Trust (210753/Z/18/Z), MRC, Parkinson’s UK, Michael J Fox Foundation, J Macdonald MenziesCharitable Trust, BBSRC, Rosetrees Trust and the EMBO-YIP program.",
year = "2019",
month = "7",
day = "13",
doi = "10.1016/j.neulet.2019.04.029",
language = "English",
volume = "705",
pages = "7--13",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier",

}

Therapeutic approaches to enhance PINK1/Parkin mediated mitophagy for the treatment of Parkinson's disease. / Miller, Silke (Lead / Corresponding author); Muqit, Miratul M. K.

In: Neuroscience Letters, Vol. 705, 13.07.2019, p. 7-13.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Therapeutic approaches to enhance PINK1/Parkin mediated mitophagy for the treatment of Parkinson's disease

AU - Miller, Silke

AU - Muqit, Miratul M. K.

N1 - Funding: Wellcome Trust (210753/Z/18/Z), MRC, Parkinson’s UK, Michael J Fox Foundation, J Macdonald MenziesCharitable Trust, BBSRC, Rosetrees Trust and the EMBO-YIP program.

PY - 2019/7/13

Y1 - 2019/7/13

N2 - The discovery of rare familial monogenic forms of early-onset Parkinson's disease has led to the identification of a mitochondrial quality control process as a key player in this disease. Loss-of-function mutations in the genes encoding PINK1 or Parkin result in insufficient removal of dysfunctional mitochondria through autophagy, a process termed mitophagy. Understanding the mechanism of this process and the function of its two key players, PINK1 and Parkin, has led to the discovery of new therapeutic approaches. Small molecule activators of mitophagy, either activating PINK1 or Parkin directly or inhibiting Parkin's counterplayer, the ubiquitin-specific protease USP30, are in preclinical development. To enable clinical success of future small molecule mitophagy enhancers, biomarkers for mitochondrial integrity and mitophagy are being developed. Only a few years after the discovery of mitophagy deficits in Parkinson's disease, research of the underlying mechanisms, drug discovery of modulators for this mechanism and identification of biomarkers provide new avenues towards the development of disease-modifying therapies.

AB - The discovery of rare familial monogenic forms of early-onset Parkinson's disease has led to the identification of a mitochondrial quality control process as a key player in this disease. Loss-of-function mutations in the genes encoding PINK1 or Parkin result in insufficient removal of dysfunctional mitochondria through autophagy, a process termed mitophagy. Understanding the mechanism of this process and the function of its two key players, PINK1 and Parkin, has led to the discovery of new therapeutic approaches. Small molecule activators of mitophagy, either activating PINK1 or Parkin directly or inhibiting Parkin's counterplayer, the ubiquitin-specific protease USP30, are in preclinical development. To enable clinical success of future small molecule mitophagy enhancers, biomarkers for mitochondrial integrity and mitophagy are being developed. Only a few years after the discovery of mitophagy deficits in Parkinson's disease, research of the underlying mechanisms, drug discovery of modulators for this mechanism and identification of biomarkers provide new avenues towards the development of disease-modifying therapies.

KW - Parkinson's disease

KW - Mitophagy

KW - PINK1

KW - Parkin

KW - USP30

KW - Small molecule

U2 - 10.1016/j.neulet.2019.04.029

DO - 10.1016/j.neulet.2019.04.029

M3 - Review article

C2 - 30995519

VL - 705

SP - 7

EP - 13

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

ER -